高级检索
当前位置: 首页 > 详情页

Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Mem Sloan Kettering Canc Ctr, Head & Neck Serv, New York, NY 10021 USA [2]Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, Dept Surg, New York, NY 10021 USA [3]Beijing Tongren Hosp, Dept Otolaryngol, Beijing, Peoples R China
出处:
ISSN:

摘要:
Purpose: Although a variety of malignant tumors are susceptible to therapy with oncolytic herpes simplex viruses, the determinants of tumor sensitivity to these viruses are poorly understood. Nectin-1 is a cell surface adhesion molecule that is a component of intercellular adherens junctions and also functions as a herpes viral receptor. Because highly invasive cells may have decreased intercellular adhesion, we sought to determine if such cells might also have altered availability of cell surface nectin-1 to act as a herpes receptor. Experimental Design and Results: A series of squamous cell carcinoma lines of increasing migratory and invasive potential, termed MG1-MG14, were selected by serial passages of murine SCC7 through Matrigel invasion chambers. Available cell surface nectin-1 was enhanced on the MG11 and MG14 cell lines in comparison to SCC7 as measured by cellular ELISA and immunofluorescence microscopy. A replication-competent, oncolytic herpes virus (NV1023) showed an increased ability to enter MG11 and MG14 cells as compared with SCC7 cells. Furthermore, MG11 and MG14 supported increased herpes viral replication and cytotoxicity over SCC7. For all three of the cell lines, viral entry assays revealed that the actively migrating cells were significantly more susceptible to herpes infection than the nonmigrating cells. Conclusions: These results show that malignant cells with highly migratory and invasive properties may exhibit increased cell surface nectin-1 availability, which may serve as a herpes viral receptor to enhance the efficacy of herpes oncolytic therapy. This finding has implications regarding patient selection for future clinical trials using these promising therapeutic vectors.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2004]版:
最新[2025]版:
大类 | 1 区 医学
小类 | 2 区 肿瘤学
JCR分区:
出版当年[2003]版:
Q1 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2003版] 出版当年五年平均 出版前一年[2002版] 出版后一年[2004版]

第一作者:
第一作者机构: [1]Mem Sloan Kettering Canc Ctr, Head & Neck Serv, New York, NY 10021 USA [3]Beijing Tongren Hosp, Dept Otolaryngol, Beijing, Peoples R China
通讯作者:
通讯机构: [1]Mem Sloan Kettering Canc Ctr, Head & Neck Serv, New York, NY 10021 USA [*1]Mem Sloan Kettering Canc Ctr, Head & Neck Serv, C-1069,1275 York Ave, New York, NY 10021 USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:25471 今日访问量:0 总访问量:1498 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)